Stockreport

Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Bellerophon Therapeutics, Inc.  (BLPH) 
Last bellerophon therapeutics, inc. earnings: 4/6 10:23 am Check Earnings Report
US:NASDAQ Investor Relations: investors.bellerophon.com
PDF WARREN, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced agreement with [Read more]